Turkiye Klinikleri Journal of Medical Sciences

.: ORIGINAL RESEARCH
Comparison of Biomarkers in Blood and Urine According to Phenotypes in Chronic Obstructive Pulmonary Disease: Cross-Sectional Research
Kronik Obstrüktif Akciğer Hastalığında Fenotiplere Göre Kanda ve İdrarda Biyobelirteçlerin Karşılaştırılması: Kesitsel Araştırma
Oylum HÜNERELa, Pınar MUTLUa, Nihal Arzu MİRİCİa, Dilek Ülker ÇAKIRb, Hakan TÜRKÖNb, Abdulhakim Hasan GÜLb
aDepartment of Chest Diseases, Çanakkale Onsekiz Mart University Faculty of Medicine, Çanakkale, Türkiye
bDepartment of Medical Biochemistry, Çanakkale Onsekiz Mart University Faculty of Medicine, Çanakkale, Türkiye
Turkiye Klinikleri J Med Sci. 2022;42(3):183-90
doi: 10.5336/medsci.2021-86396
Article Language: EN
Full Text
ABSTRACT
 Objective: Chronic obstructive pulmonary disease (COPD) is one of the leading causes of morbidity and mortality worldwide. Biomarkers have been recognized as an important tool in assessing COPD patients. In this study, we aimed to investigate the possible relationship between certain biomarkers and different COPD phenotypes. Material and Methods: Between January 1, 2017-December 31, 2017, a total of 85 patients who were admitted to the Çanakkale Onsekiz Mart University Faculty of Medicine Hospital Chest Diseases Outpatient Clinic with a diagnosis of COPD according to the Global Initiative for Chronic Obstructive Lung Disease 2017 Guidelines were included in this study. All patients filled in the COPD Assessment Test and modified Medical Research Council questionnaires. Patients were divided into 4 phenotypes: emphysema, chronic bronchitis, frequent exacerbation, and asthma COPD overlap syndrome (ACOS). Levels of C-reactive protein (CRP), desmosine, fibronectin, eotaxin, and interleukin (IL)-2 were measured and compared between the phenotypes. Results: The mean age was 64.56 years and 92.9% of the study population were males. Of 85 patients, 43 had emphysema, 13 had frequent exacerbation, 15 had chronic bronchitis, and 14 had ACOS phenotype. Blood fibronectin, eotaxin, and urine desmosine levels were significantly lower in patients with ACOS phenotype compared to the other phenotypes. In patients with the frequent exacerbation phenotype, the CRP level was significantly higher than that of the other three phenotypes. The IL-2 levels were similar in all phenotypes. Conclusion: Our study results suggest that these biomarkers may be useful in the differential diagnosis of COPD phenotypes.

Keywords: Pulmonary disease; chronic obstructive; phenotype; biomarkers
ÖZET
 Amaç: Kronik obstrüktif akciğer hastalığı (KOAH), ülkemiz ve tüm dünya ülkelerinde önemli mortalite ve morbidite nedeni olan bir hastalıktır. Biyomarker ölçümleri KOAH'ın değerlendirilmesinde giderek daha önemli bir hâl almaktadır. Çalışmamızın amacı, biyomarker düzeylerinin KOAH fenotipleri arasında anlamlı farklılık gösterip göstermediğini araştırmaktır. Gereç ve Yöntemler: Çalışmamıza, 1 Ocak 2017-31 Aralık 2017 tarihleri arasında, Çanakkale Onsekiz Mart Üniversitesi Tıp Fakültesi Hastanesi Göğüs Hastalıkları Polikliniğine başvuran, KOAH tanılı veya 'Global Initiative for Chronic Obstructive Lung Disease' 2017 kılavuzuna göre KOAH tanısı konulan 85 hasta alınmıştır. Hastalar, KOAH değerlendirme Testi ve 'modifiye Medical Research Council' anketleri doldurmuştur. Amfizem, sık alevlenenler, kronik bronşit ve astım-KOAH ortak sendromu (AKOS) olmak üzere 4 fenotipe ayrılmıştır. Hastalardan venöz kan örneği ve idrar örneği alınmıştır. C-reaktif protein (CRP), desmozin, eotaksin, fibronektin ve interlökin-2 (IL-2) biyobelirteç düzeyleri belirlenmiştir. Bulgular: Araştırmaya katılan hastaların yaş ortalaması 64,56'dır. Örneklemin %92,9'u erkektir. Toplam 85 hastanın 43'ü amfizem, 13'ü sık alevlenen, 15'i kronik bronşit, 14'ü AKOS fenotipindedir. Kan fibronektin, eotaksin ve idrar desmozin düzeyi AKOS fenotipindeki hastalarda diğer fenotiplerin tümünden anlamlı derecede düşüktür. Sık alevlenen fenotipindeki hastalarda CRP düzeyi diğer fenotiplerin tümünden anlamlı derecede yüksektir. Fenotipler arasında, IL-2 düzeyi ortalamaları açısından fark yoktur. Sonuç: Çalışmamız sonucunda, KOAH fenotipleri arasında biyobelirteç düzeyleri açısından anlamlı farklılıklar bulunmuş olup; çalışmamızın, bu konuda yapılacak daha kapsamlı araştırmalara ışık tutacağı kanaatindeyiz.

Anahtar Kelimeler: Akciğer hastalığı; kronik obstrüktif; fenotip; biyobelirteçler
REFERENCES:
  1. Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease 2022 Report. Global Initiative for Chronic Obstructive Lung Disease Inc; 2022. [Link] 
  2. Corlateanu A, Mendez Y, Wang Y, Garnica RJA, Botnaru V, Siafakas N. "Chronic obstructive pulmonary disease and phenotypes: a state-of-the-art." Pulmonology. 2020;26(2):95-100. [Crossref]  [PubMed] 
  3. Hernández Vázquez J, Ali García I, Jiménez-García R, Álvaro Meca A, López de Andrés A, Matesanz Ruiz C, et al. COPD phenotypes: differences in survival. Int J Chron Obstruct Pulmon Dis. 2018;13:2245-51. [Crossref]  [PubMed]  [PMC] 
  4. Leung JM, Sin DD. Biomarkers in airway diseases. Can Respir J. 2013;20(3):180-2. [Crossref]  [PubMed]  [PMC] 
  5. Agustí A, Edwards LD, Rennard SI, MacNee W, Tal-Singer R, Miller BE, et al; Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints (ECLIPSE) Investigators. Persistent systemic inflammation is associated with poor clinical outcomes in COPD: a novel phenotype. PLoS One. 2012;7(5):e37483. [Crossref]  [PubMed]  [PMC] 
  6. Annoni R, Lanças T, Yukimatsu Tanigawa R, de Medeiros Matsushita M, de Morais Fernezlian S, Bruno A, et al. Extracellular matrix composition in COPD. Eur Respir J. 2012;40(6):1362-73. [Crossref]  [PubMed] 
  7. Zhang Y, Ren L, Sun J, Han F, Guo X. Increased serum soluble interleukin-2 receptor associated with severity of acute exacerbation of chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis. 2021;16:2561-73. [Crossref]  [PubMed]  [PMC] 
  8. Hao W, Li M, Zhang Y, Zhang C, Wang P. Severity of chronic obstructive pulmonary disease with 'exacerbator with emphysema phenotype' is associated with potential biomarkers. Postgrad Med J. 2020;96(1131):28-32. [Crossref]  [PubMed] 
  9. Kim C, Ko Y, Kim SH, Yoo HJ, Lee JS, Rhee CK, et al. Urinary desmosine is associated with emphysema severity and frequent exacerbation in patients with COPD. Respirology. 2018;23(2):176-81. [Crossref]  [PubMed] 
  10. Miravitlles M, Soler-Catalu-a JJ, Calle M, Molina J, Almagro P, Quintano JA, et al. A new approach to grading and treating COPD based on clinical phenotypes: summary of the Spanish COPD guidelines (GesEPOC). Prim Care Respir J. 2013;22(1):117-21. [Crossref]  [PubMed]  [PMC] 
  11. Wu JJ, Xu HR, Zhang YX, Li YX, Yu HY, Jiang LD, et al. The characteristics of the frequent exacerbator with chronic bronchitis phenotype and non-exacerbator phenotype in patients with chronic obstructive pulmonary disease: a meta-analysis and system review. BMC Pulm Med. 2020;20(1):103. [Crossref]  [PubMed]  [PMC] 
  12. Kania A, Krenke R, Kuziemski K, Czajkowska-Malinowska M, Celejewska-Wójcik N, Kuźnar-Kamińska B, et al. Distribution and characteristics of COPD phenotypes-results from the Polish sub-cohort of the POPE study. Int J Chron Obstruct Pulmon Dis. 2018;13:1613-21. [Crossref]  [PubMed]  [PMC] 
  13. Bujarski S, Parulekar AD, Sharafkhaneh A, Hanania NA. The asthma COPD overlap syndrome (ACOS). Curr Allergy Asthma Rep. 2015;15(3):509. [Crossref]  [PubMed] 
  14. Mackay AJ, Donaldson GC, Patel AR, Jones PW, Hurst JR, Wedzicha JA. Usefulness of the Chronic Obstructive Pulmonary Disease Assessment Test to evaluate severity of COPD exacerbations. Am J Respir Crit Care Med. 2012;185(11):1218-24. [Crossref]  [PubMed] 
  15. Weiss DJ, Segal K, Casaburi R, Hayes J, Tashkin D. Effect of mesenchymal stromal cell infusions on lung function in COPD patients with high CRP levels. Respir Res. 2021;22(1):142. [Crossref]  [PubMed]  [PMC] 
  16. Munuswamy R, De Brandt J, Burtin C, Derave W, Aumann J, Spruit MA, et al. Monomeric CRP is elevated in patients with COPD compared to non-COPD control persons. J Inflamm Res. 2021;14:4503-7. [Crossref]  [PubMed]  [PMC] 
  17. Julike K, Tarigan AP, Ganie RA. The relationship between forced expiratory volume 1 (FEV 1) with 25(OH) vitamin D level and hs-CRP in COPD in H. Adam Malik General Hospital Medan. Indonesia Journal of Biomedical Science. 2019;13(1):16-21. [Crossref] 
  18. Díaz O, Parada A, Ramos C, Klaassen J, Díaz JC, Andresen M, et al. Proteína C Reactiva en la EPOC y su relación con la gravedad de la enfermedad, las exacerbaciones y las comorbilidades [C-Reactive protein levels in patients with chronic obstructive pulmonary disease]. Rev Med Chile. 2012;140:569-78. [Crossref]  [PubMed] 
  19. Devenport NA, Reynolds JC, Parkash V, Cook J, Weston DJ, Creaser CS. Determination of free desmosine and isodesmosine as urinary biomarkers of lung disorder using ultra performance liquid chromatography-ion mobility-mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci. 2011;879(32):3797-801. [Crossref]  [PubMed] 
  20. Cocci F, Miniati M, Monti S, Cavarra E, Gambelli F, Battolla L, et al. Urinary desmosine excretion is inversely correlated with the extent of emphysema in patients with chronic obstructive pulmonary disease. Int J Biochem Cell Biol. 2002;34(6):594-604. [Crossref]  [PubMed] 
  21. Huang JT, Chaudhuri R, Albarbarawi O, Barton A, Grierson C, Rauchhaus P, et al. Clinical validity of plasma and urinary desmosine as biomarkers for chronic obstructive pulmonary disease. Thorax. 2012;67(6):502-8. [Crossref]  [PubMed]  [PMC] 
  22. Man SF, Xing L, Connett JE, Anthonisen NR, Wise RA, Tashkin DP, et al. Circulating fibronectin to C-reactive protein ratio and mortality: a biomarker in COPD? Eur Respir J. 2008;32(6):1451-7. [Crossref]  [PubMed] 
  23. Kicic A, Hallstrand TS, Sutanto EN, Stevens PT, Kobor MS, Taplin C, et al. Decreased fibronectin production significantly contributes to dysregulated repair of asthmatic epithelium. Am J Respir Crit Care Med. 2010;181(9):889-98. [Crossref]  [PubMed]  [PMC] 
  24. Tateno H, Nakamura H, Minematsu N, Nakajima T, Takahashi S, Nakamura M, et al. Plasma eotaxin level and severity of asthma treated with corticosteroid. Respir Med. 2004;98(8):782-90. [Crossref]  [PubMed] 
  25. Paplińska M, Hermanowicz-Salamon J, Nejman-Gryz P, Białek-Gosk K, Rubinsztajn R, Arcimowicz M, et al. Expression of eotaxins in the material from nasal brushing in asthma, allergic rhinitis and COPD patients. Cytokine. 2012;60(2):393-9. [Crossref]  [PubMed] 
  26. Ghosh N, Choudhury P, Kaushik SR, Arya R, Nanda R, Bhattacharyya P, et al. Metabolomic fingerprinting and systemic inflammatory profiling of asthma COPD overlap (ACO). Respir Res. 2020;21(1):126. [Crossref]  [PubMed]  [PMC] 
  27. Lababidi R, Cane J, Bafadhel M. P54 Eosinophil migration is enhanced towards IL-5 and eotaxin in COPD. Thorax. 2017;72:A111-2. [Crossref] 
  28. Bade G, Khan MA, Srivastava AK, Khare P, Solaiappan KK, Guleria R, et al. Serum cytokine profiling and enrichment analysis reveal the involvement of immunological and inflammatory pathways in stable patients with chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis. 2014;9:759-73. [Crossref]  [PubMed]  [PMC] 
  29. D'Armiento JM, Scharf SM, Roth MD, Connett JE, Ghio A, Sternberg D, et al. Eosinophil and T cell markers predict functional decline in COPD patients. Respir Res. 2009;10(1):113. [Crossref]  [PubMed]  [PMC] 
  30. Adnan AM, Ammar AZ, Khalil K. Role of eotaxin in chronic obstructive pulmonary disease. International Journal of Pharmaceutical Sciences Review and Research. 2013;21(1):10-4. [Link] 
  31. Tzanakis N, Chrysofakis G, Tsoumakidou M, Kyriakou D, Tsiligianni J, Bouros D, et al. Induced sputum CD8+ T-lymphocyte subpopulations in chronic obstructive pulmonary disease. Respir Med. 2004;98(1):57-65. [Crossref]  [PubMed] 
  32. Saetta M, Baraldo S, Corbino L, Turato G, Braccioni F, Rea F, et al. CD8+ve cells in the lungs of smokers with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 1999;160(2):711-7. [Crossref]  [PubMed] 
  33. O'Shaughnessy TC, Ansari TW, Barnes NC, Jeffery PK. Inflammation in bronchial biopsies of subjects with chronic bronchitis: inverse relationship of CD8+ T lymphocytes with FEV1. Am J Respir Crit Care Med. 1997;155(3):852-7. [Crossref]  [PubMed] 
  34. Saetta M, Di Stefano A, Turato G, Facchini FM, Corbino L, Mapp CE, et al. CD8+ T-lymphocytes in peripheral airways of smokers with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 1998;157(3 Pt 1):822-6. [Crossref]  [PubMed] 
  35. Robbins CS, Franco F, Mouded M, Cernadas M, Shapiro SD. Cigarette smoke exposure impairs dendritic cell maturation and T cell proliferation in thoracic lymph nodes of mice. J Immunol. 2008;180(10):6623-8. [Crossref]  [PubMed]  [PMC] 

.: Up To Date

.: Process List

Login

 Forgot your password?

 New Registration  

Contact

Ortadoğu Reklam Tanıtım Yayıncılık Turizm Eğitim İnşaat Sanayi ve Ticaret A.Ş.

.: Address

Turkocagi Caddesi No:30 06520 Balgat / ANKARA
Phone: +90 312 286 56 56
Fax: +90 312 220 04 70
E-mail: info@turkiyeklinikleri.com

.: Manuscript Editing Department

Phone: +90 312 286 56 56/ 2
E-mail: yaziisleri@turkiyeklinikleri.com

.: English Language Redaction

Phone: +90 312 286 56 56/ 145
E-mail: tkyayindestek@turkiyeklinikleri.com

.: Marketing Sales-Project Department

Phone: +90 312 286 56 56/ 142
E-mail: reklam@turkiyeklinikleri.com

.: Subscription and Public Relations Department

Phone: +90 312 286 56 56/ 118
E-mail: abone@turkiyeklinikleri.com

.: Customer Services

Phone: +90 312 286 56 56/ 118
E-mail: satisdestek@turkiyeklinikleri.com

1. TERMS OF USE

1.1. To use the web pages with http://www.turkiyeklinikleri.com domain name or the websites reached through the sub domain names attached to the domain name (They will be collectively referred as "SITE"), please read the conditions below. If you do not accept these terms, please cease to use the "SITE." "SITE" owner reserves the right to change the information on the website, forms, contents, the "SITE," "SITE" terms of use anytime they want.

1.2. The owner of the "SITE" is Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc. (From now on it is going to be referred as "Turkiye Klinikleri", shortly) and it resides at Turkocagi cad. No:30, 06520 Balgat Ankara. The services in the "SITE" are provided by "Turkiye Klinikleri."

1.3. Anyone accessing the "SITE" with or without a fee whether they are a natural person or a legal identity is considered to agree these terms of use. In this contract hereby, "Turkiye Klinikleri" may change the stated terms anytime. These changes will be published in the "SITE" periodically and they will be valid when they are published. Any natural person or legal identity benefiting from and reaching to the "SITE" are considered to be agreed to any change on hereby contract terms done by "Turkiye Klinikleri."

1.4. The "Terms of Use" hereby is published in the website with the last change on March 30th 2014 and the "SITE" is activated by enabling the access to everyone. The "Terms of Use" hereby is also a part of the any "USER Contract" was and/or will be done with the users using "Turkiye Klinikleri" services with or without a fee an inseparable.

2. DEFINITIONS

2.1. "SITE": A website offering different kind of services and context with a certain frame determined by "Turkiye Klinikleri" and it is accessible on-line on http://www.turkiyeklinikleri.com domain name and/or subdomains connected to the domain name.

2.2. USER: A natural person or a legal identity accessing to the "SITE" through online settings.

2.3. LINK: A link enabling to access to another website through the "SITE", the files, the context or through another website to the "SITE", the files and the context.

2.4. CONTEXT: Any visual, literary and auditory images published in the "Turkiye Klinikleri", "SITE" and/or any website or any accessible information, file, picture, number/figures, price, etc.

2.5. "USER CONTRACT": An electronically signed contract between a natural or a legal identity benefiting from special services "Turkiye Klinikleri" will provide and "Turkiye Klinikleri".

3. SCOPE OF THE SERVICES

3.1. "Turkiye Klinikleri" is completely free to determine the scope and quality of the services via the "SITE".

3.2. To benefit the services of "Turkiye Klinikleri" "SITE", the "USER" must deliver the features that will be specified by "Turkiye Klinikleri". "Turkiye Klinikleri" may change this necessity any time single-sided.

3.3. Not for a limited number, the services "Turkiye Klinikleri" will provide through the "SITE" for a certain price or for free are;

- Providing scientific articles, books and informative publications for health industry.

- Providing structural, statistical and editorial support to article preparation stage for scientific journals.

4. GENERAL PROVISIONS

4.1. "Turkiye Klinikleri" is completely free to determine which of the services and contents provided in the "SITE" will be charged.

4.2. People benefiting from the services provided by "Turkiye Klinikleri" and using the website can use the "SITE" only according to the law and only for personal reasons. Users have the criminal and civil liability for every process and action they take in the "SITE". Every USER agrees, declares and undertakes that they will not proceed by any function or action infringement of rights of "Turkiye Klinikleri"s and/or other third parties', they are the exclusive right holder on usage, processing, storage, made public and revealing any written, visual or auditory information reported to Turkiye Klinikleri" and/or "SITE" to the third parties. "USER" agrees and undertakes that s/he will not duplicate, copy, distribute, process, the pictures, text, visual and auditory images, video clips, files, databases, catalogs and lists within the "SITE", s/he will not be using these actions or with other ways to compete with "Turkiye Klinikleri", directly or indirectly.

4.3. The services provided and the context published within the "SITE" by third parties is not under the responsibility of "Turkiye Klinikleri", institutions collaborated with "Turkiye Klinikleri", "Turkiye Klinikleri" employee and directors, "Turkiye Klinikleri" authorized salespeople. Commitment to accuracy and legality of the published information, context, visual and auditory images provided by any third party are under the full responsibility of the third party. "Turkiye Klinikleri" does not promise and guarantee the safety, accuracy and legality of the services and context provided by a third party.

4.4. "USER"s cannot act against "Turkiye Klinikleri", other "USER"s and third parties by using the "SITE". "Turkiye Klinikleri" has no direct and/or indirect responsibility for any damage a third party suffered or will suffer regarding "USER"s actions on the "SITE" against the rules of the hereby "Terms of Use" and the law.

4.5. "USER"s accept and undertake that the information and context they provided to the "SITE" are accurate and legal. "Turkiye Klinikleri" is not liable and responsible for promising and guaranteeing the verification of the information and context transmitted to "Turkiye Klinikleri" by the "USER"s, or uploaded, changed and provided through the "SITE" by them and whether these information are safe, accurate and legal.

4.6. "USER"s agree and undertake that they will not perform any action leading to unfair competition, weakening the personal and commercial credit of "Turkiye Klinikleri" and a third party,  encroaching and attacking on personal rights within the "SITE" in accordance with the Turkish Commercial Code Law.

4.7. "Turkiye Klinikleri" reserves the right to change the services and the context within the "SITE"  anytime. "Turkiye Klinikleri" may use this right without any notification and timelessly. "USER"s have to make the changes and/or corrections "Turkiye Klinikleri" required immediately. Any changes and/or corrections that are required by "Turkiye Klinikleri", may be made by "Turkiye Klinikleri" when needed. Any harm, criminal and civil liability resulted or will result from changes and/or corrections required by "Turkiye Klinikleri" and were not made on time by the "USER"s belongs completely to the users.

4.8. "Turkiye Klinikleri" may give links through the "SITE" to other websites and/or "CONTEXT"s and/or folders that are outside of their control and owned and run by third parties. These links are provided for ease of reference only and do not hold qualification for support the respective web SITE or the admin or declaration or guarantee for the information inside. "Turkiye Klinikleri" does not hold any responsibility over the web-sites connected through the links on the "SITE", folders and context, the services or products on the websites provided through these links or their context.

4.9. "Turkiye Klinikleri" may use the information provided to them by the "USERS" through the "SITE" in line with the terms of the "PRIVACY POLICY" and "USER CONTRACT". It may process the information or classify and save them on a database. "Turkiye Klinikleri" may also use the USER's or visitor's identity, address, e-mail address, phone number, IP number, which sections of the "SITE" they visited, domain type, browser type, date and time information to provide statistical evaluation and customized services.

5. PROPRIETARY RIGHTS

5.1. The information accessed through this "SITE" or provided by the users legally and all the elements (including but not limited to design, text, image, html code and other codes) of the "SITE" (all of them will be called as studies tied to "Turkiye Klinikleri"s copyrights) belongs to "Turkiye Klinikleri". Users do not have the right to resell, process, share, distribute, display or give someone permission to access or to use the "Turkiye Klinikleri" services, "Turkiye Klinikleri" information and the products under copyright protection by "Turkiye Klinikleri". Within hereby "Terms of Use" unless explicitly permitted by "Turkiye Klinikleri" nobody can reproduce, process, distribute or produce or prepare any study from those under "Turkiye Klinikleri" copyright protection.

5.2. Within hereby "Terms of Use", "Turkiye Klinikleri" reserves the rights for "Turkiye Klinikleri" services, "Turkiye Klinikleri" information, the products associated with "Turkiye Klinikleri" copyrights, "Turkiye Klinikleri" trademarks, "Turkiye Klinikleri" trade looks or its all rights for other entity and information it has through this website unless it is explicitly authorized by "Turkiye Klinikleri".

6. CHANGES IN THE TERMS OF USE

"Turkiye Klinikleri" in its sole discretion may change the hereby "Terms of Use" anytime announcing within the "SITE". The changed terms of the hereby "Terms of Use" will become valid when they are announced. Hereby "Terms of Use" cannot be changed by unilateral declarations of users.

7. FORCE MAJEURE

"Turkiye Klinikleri" is not responsible for executing late or never of this hereby "Terms of Use", privacy policy and "USER Contract" in any situation legally taken into account as force majeure. Being late or failure of performance or non-defaulting of this and similar cases like this will not be the case from the viewpoint of "Turkiye Klinikleri", and "Turkiye Klinikleri" will not have any damage liability for these situations. "Force majeure" term will be regarded as outside of the concerned party's reasonable control and any situation that "Turkiye Klinikleri" cannot prevent even though it shows due diligence. Also, force majeure situations include but not limited to natural disasters, rebellion, war, strike, communication problems, infrastructure and internet failure, power cut and bad weather conditions.

8. LAW AND AUTHORISATION TO FOLLOW

Turkish Law will be applied in practicing, interpreting the hereby "Terms of Use" and managing the emerging legal relationships within this "Terms of Use" in case of finding element of foreignness, except for the rules of Turkish conflict of laws. Ankara Courts and Enforcement Offices are entitled in any controversy happened or may happen due to hereby contract.

9. CLOSING AND AGREEMENT

Hereby "Terms of Use" come into force when announced in the "SITE" by "Turkiye Klinikleri". The users are regarded to agree to hereby contract terms by using the "SITE". "Turkiye Klinikleri" may change the contract terms and the changes will be come into force by specifying the version number and the date of change on time it is published in the "SITE".

 

30.03.2014

Privacy Policy

We recommend you to read the terms of use below before you visit our website. In case you agree these terms, following our rules will be to your favor. Please read our Terms of Use thoroughly.

www.turkiyeklinikleri.com website belongs to Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc. and is designed in order to inform physicians in the field of health

www.turkiyeklinikleri.com cannot reach to user’s identity, address, service providers or other information. The users may send this information to the website through forms if they would like to. However, www.turkiyeklinikleri.com may collect your hardware and software information. The information consists of your IP address, browser type, operating system, domain name, access time, and related websites. www.turkiyeklinikleri.com cannot sell the provided user information (your name, e-mail address, home and work address, phone number) to the third parties, publish it publicly, or keep it in the website. Gathered information has a directing feature to be a source for the website’s visitor profile, reporting and promotion of the services.

www.turkiyeklinikleri.com uses the taken information:

-To enhance, improve and maintain the quality of the website

-To generate visitor’s profile and statistical data

-To determine the tendency of the visitors on using our website

-To send print publications/correspondences

-To send press releases or notifications through e-mail

-To generate a list for an event or competition

By using www.turkiyeklinikleri.com you are considered to agree that;

-Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc. cannot be hold responsible for any user’s illegal and immoral behavior,

-Terms of use may change from time to time,

-It is not responsible for other websites’ contents it cannot control or the harms they may cause although it uses the connection they provided.

Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc. may block the website to users in the following events:

-Information with wrong, incomplete, deceiving or immoral expressions is recorded to the website,

-Proclamation, advertisement, announcement, libelous expressions are used against natural person or legal identity,

-During various attacks to the website,

-Disruption of the website because of a virus.

Written, visual and audible materials of the website, including the code and the software are under protection by legal legislation.

Without the written consent of Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc. the information on the website cannot be downloaded, changed, reproduced, copied, republished, posted or distributed.

All rights of the software and the design of the website belong to Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc.

Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc. will be pleased to hear your comments about our terms of use. Please share the subjects you think may enrich our website or if there is any problem regarding our website.

info@turkiyeklinikleri.com